Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2021

Yin Lingdi, Pu Ning, Thompson Elizabeth, Miao Yi, Wolfgang Christopher, Yu Jun

Abstract excerpt

PURPOSE: To evaluate somatic mutations, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in patients with Pancreatic ductal adenocarcinoma (PDAC) with pathologic complete response (pCR) to neoadjuvant therapy (NAT) and find their associations with outcome. EXPERIMENTAL DESIGN: Thirty-six patients with PDAC with pCR were identified from 2009 to 2017. Macrodissection was performed on resected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Irinotecan

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucovorin

Share to Liquid Biopsy

Share to Neoadjuvant Therapy

Share to Neoplastic Cells, Circulating

Share to Oxaliplatin

Share to Pancreatectomy

Source

Identifiers

PMID: 33082211
DOI: 10.1158/1078-0432.CCR-20-1746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.PMID 33082211Read ↗

A step towards personalizing next line therapy for resected pancreatic and related cancer patients: A single institution's experience.Semantic proximity Read ↗

Building on the clinical applicability of ctDNA analysis in non-metastatic pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Molecular classification as prognostic factor and guide for treatment decision of pancreatic cancer.Semantic proximity Read ↗

ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients.Semantic proximity Read ↗

Molecular Profiling and Survival Outcomes in Pancreatic Ductal Adenocarcinoma: A Multicenter Real-World Study from Turkey.Semantic proximity Read ↗

Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.Semantic proximity Read ↗

Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelSemantic proximity Read ↗

Targeted Therapies in Pancreatic Cancer: A New Era of Precision MedicineSemantic proximity Read ↗

Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Clinical utility of molecular subtyping of pancreatic cancerSemantic proximity Read ↗

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.